PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights • Key buying criteria PART 05: Disease overview • Introduction • Risk factors • Diagnosis • Management • Epidemiology • Economic burden PART 06: Pipeline portfolio PART 07: Market landscape • Global diabetes drugs market • Global type 2 diabetes drugs market • Five forces analysis PART 08: Market segmentation by drug class PART 09: Insulin • Product portfolio • Global insulin market PART 10: DPP-4 inhibitors • Market overview • Market size and forecast PART 11: GLP-1 receptor agonists • Market overview • Market size and forecast PART 12: SGLT-2 inhibitors • Market overview • Market size and forecast PART 13: Geographical segmentation • Global type 2 diabetes drugs market by geographical segmentation 2015-2020 • Type 2 diabetes drugs market in Americas • Type 2 diabetes drugs market in EMEA • Type 2 diabetes drugs market in APAC PART 14: Market drivers • Rising prevalence of diabetes • Rise in obesity rates • Growing older population • Unmet medical needs • Stringent regulatory guidelines for biosimilar drugs PART 15: Impact of drivers PART 16: Market challenges • Low diagnosis rate • Rising concerns in scientific community • Gaps in national-level diabetes management plans • Poor storage conditions and distribution policies for insulin • Fierce market competition PART 17: Impact of drivers and challenges PART 18: Market trends • Increase in awareness of diabetes • Increase in academia-industry collaboration • Rising price of diabetes drugs • Increase in R&D PART 19: Vendor landscape • Competitive scenario • Market analysis 2015 • Novo Nordisk • Sanofi • Merck • Eli Lilly • AstraZeneca • Other prominent vendors PART 20: Appendix0 • List of abbreviations PART 21: Explore Technavio1 List of Exhibits Exhibit 01: Product offerings Exhibit 02: Key buying criteria for type 2 diabetes drugs Exhibit 03: Line of therapy for type 2 diabetes Exhibit 04: Pipeline portfolio: Global type 2 diabetes drugs market Exhibit 05: Global diabetes drugs market by prevalence based on type of disease 2015 Exhibit 06: Top selling diabetes drugs based on sales 2014 ($ billions) Exhibit 07: Market share of global diabetes drugs in global pharmaceutical drugs market 2015 Exhibit 08: Global diabetes drugs market 2015-2020 ($ billions) Exhibit 09: Market share analysis of vendors in global diabetes drugs market Exhibit 10: Global type 2 diabetes drugs market 2015-2020 ($ billions) Exhibit 11: Five forces analysis Exhibit 12: Segmentation of global type 2 diabetes drugs market by drug class Exhibit 13: Segmentation of global type 2 diabetes drugs market by drug class 2015 Exhibit 14: Comparison of different classes of type 2 diabetes drugs Exhibit 15: Global human insulin market 2015-2020 ($ billions) Exhibit 16: Global insulin market revenues by type of diabetes 2015 Exhibit 17: Segmentation of global insulin market based by drug class 2015 Exhibit 18: Segmentation of global insulin market by geography 2015 Exhibit 19: DPP-4 inhibitor drugs approved in market Exhibit 20: Global DPP-4 inhibitors drugs market for type 2 diabetes 2015-2020 ($ billions) Exhibit 21: GLP-1 receptor agonists approved in market Exhibit 22: Global GLP-1 receptor agonists drugs market for type 2 diabetes 2015-2020 ($ billions) Exhibit 23: Segmentation of global GLP-1 receptor agonists drugs market for type 2 diabetes by geography 2015 Exhibit 24: Approved SGLT-2 inhibitor drugs Exhibit 25: Global SGLT-2 inhibitors market for type 2 diabetes 2015-2020 ($ billions) Exhibit 26: Segmentation of global type 2 diabetes drugs market by geography 2015 Exhibit 27: Global type 2 diabetes drugs market revenue by geography 2015-2020 ($ billions) Exhibit 28: Percentage share of global type 2 diabetes drugs market by geography 2015-2020 Exhibit 29: Type 2 diabetes drugs market in Americas 2015-2020 ($ billions) Exhibit 30: Segmentation of type 2 diabetes drugs market in Americas by country 2015 Exhibit 31: Type 2 diabetes drugs market in US 2015-2020 ($ billions) Exhibit 32: Type 2 diabetes drugs market in Brazil 2015-2020 ($ billions) Exhibit 33: Type 2 diabetes drugs market in EMEA 2015-2020 ($ billions) Exhibit 34: Type 2 diabetes drugs market in APAC 2015-2020 ($ billions) Exhibit 35: Segmentation of type 2 diabetes drugs market in APAC by country 2015 Exhibit 36: Global type 2 diabetes drugs market: YoY growth and revenue based on geography 2015-2020 Exhibit 37: Impact of drivers Exhibit 38: Impact of drivers and challenges Exhibit 39: YOY revenues from sales of top seven products in global type 2 diabetes drugs market 2012-2014 ($ billions) Exhibit 40: Novo Nordisk: Business segmentation by revenue 2015 Exhibit 41: Novo Nordisk: R&D expenditure 2015 Exhibit 42: Novo Nordisk: Key product offerings in global type 2 diabetes drugs market Exhibit 43: Novo Nordisk: YoY revenue and growth rate generated from net product sales of human insulins 2012-2015 ($ billions) Exhibit 44: Novo Nordisk: YoY revenue and growth rate generated from net product sales of Levemir 2012-2015 ($ billions) Exhibit 45: Novo Nordisk: YoY revenue and growth rate of NovoRapid/NovoLog 2012-2015 ($ billions) Exhibit 46: Novo Nordisk: Revenues of NovoRapid/NovoLog by geography 2015 Exhibit 47: Novo Nordisk: YoY revenue and growth rate of NovoMix/NovoLog Mix 2012-2015 ($ billions) Exhibit 48: Novo Nordisk: Revenues of NovoMix/NovoLog Mix by geography 2015 Exhibit 49: Novo Nordisk: YOY revenue and growth rate generated from net product sales of new-generation insulins 2013-2015 ($ millions) Exhibit 50: Novo Nordisk: YoY revenue and growth rate of Victoza 2012-2015 ($ billions) Exhibit 51: Novo Nordisk: YoY revenue and growth rate of Victoza in US 2013-2015 ($ billions) Exhibit 52: Novo Nordisk: YoY revenue and growth rate of Victoza in Europe 2013-2015 ($ billions) Exhibit 53: Novo Nordisk: YoY revenue and growth rate of Novonorm, Prandin, and Prandimet 2012-2014 ($ billions) Exhibit 54: Novo Nordisk: Key takeaways Exhibit 55: Sanofi: Business segmentation by revenue 2015 Exhibit 56: Sanofi: Key product offerings in global type 2 diabetes drugs market Exhibit 57: Sanofi: YoY revenue and growth rate of Lantus 2012-2015 ($ billions) Exhibit 58: Sanofi: Geographical segmentation of Lantus by revenue 2015 Exhibit 59: Sanofi: YoY revenue and growth rate of Amaryl 2012-2015 ($ millions) Exhibit 60: Sanofi: Geographical segmentation of Amaryl by revenue 2015 Exhibit 61: Sanofi: YoY revenue and growth rate of Apidra 2012-2015 ($ millions) Exhibit 62: Sanofi: Geographical segmentation of Toujeo by revenue 2015 Exhibit 63: Sanofi: YoY revenue and growth rate of Insuman 2012-2015 ($ millions) Exhibit 64: Sanofi: YoY revenue and growth rate of Lyxumia 2013-2015 ($ millions) Exhibit 65: Sanofi: Key takeaways Exhibit 66: Merck: Business segmentation by revenue 2015 Exhibit 67: Merck: Diabetes segmentation by revenue 2015 Exhibit 68: Merck: Key product offerings in global type 2 diabetes drugs market Exhibit 69: Merck: YoY revenue and growth rate of Janumet 2012-2015 ($ billions) Exhibit 70: Merck: YoY revenue and growth rate of Januvia from 2012-2015 ($ billions) Exhibit 71: Merck: Key takeaways0 Exhibit 72: Eli Lilly: Key product offerings in global type 2 diabetes drugs market1 Exhibit 73: Eli Lilly: YoY revenue and growth rate of Humalog 2012-2015 ($ billions)1 Exhibit 74: Eli Lilly: YoY revenue and growth rate of Humalog in US 2013-2015 ($ billions)2 Exhibit 75: Eli Lilly: YoY revenue and growth rate of Humalog in ROW 2013-2015 ($ billions)2 Exhibit 76: Eli Lilly: YoY revenue and growth rate of Humulin 2012-2015 ($ billions)3 Exhibit 77: Eli Lilly: YoY revenue and growth rate of Humulin in US 2013-2015 ($ millions)3 Exhibit 78: Eli Lilly: YoY revenue and growth rate of Humulin in ROW 2013-2015 ($ millions)3 Exhibit 79: Eli Lilly: YoY revenue and growth rate of Tradjenta 2012-2015 ($ millions)4 Exhibit 80: Eli Lilly: YoY revenue of Trulicity 2014-2015 ($ millions)5 Exhibit 81: Eli Lilly: Trulicity geographical segmentation by revenue 20155 Exhibit 82: Eli Lilly: Key takeaways7 Exhibit 83: AstraZeneca: Key product offerings in global type 2 diabetes drugs market9 Exhibit 84: AstraZeneca: Farxiga/Forxiga geographical segmentation by revenues 20159 Exhibit 85: AstraZeneca: YoY revenues and growth rate of Byetta 2012-2015 ($ millions)0 Exhibit 86: AstraZeneca: YoY revenues and growth rate of Byetta in US ($ millions)0 Exhibit 87: AstraZeneca: YoY revenues and growth rate of Bydureon 2012-2015 ($ millions)1 Exhibit 88: AstraZeneca: YoY revenues and growth rate of Bydureon in US ($ millions)1 Exhibit 89: AstraZeneca: YoY revenues and growth rate of Onglyza 2012-2015 ($ millions)2 Exhibit 90: AstraZeneca: YoY revenues and growth rate of Onglyza/Kombiglyze XR/Komboglyze in US ($ millions)2 Exhibit 91: AstraZeneca: Key takeaways

AstraZeneca plc, Eli Lilly and Company, Merck & Co. Inc., Novo Nordisk A/S, Sanofi SA, Adocia, Akros Pharma, Amgen, Astellas Pharma, Biocon, Boehringer Ingelheim, Chipscreen Biosciences, ConjuChem, CymaBay Therapeutics, Daiichi Sankyo, DiaMedica, Diasome Pharmaceuticals, Dong-A ST, Elcelyx Therapeutics, Exsulin, Generex, Genfit, Hanmi, Hua Medicine, InteKrin Therapeutics, Ionis Pharmaceuticals, Janssen Pharmaceuticals, Japan Tobacco, Kadmon, KinDex Pharmaceuticals, Kissei, Kotobuki Pharmaceutical, Lexicon Pharmaceuticals, Ligand, MannKind, MedImmune, Melior Pharmaceuticals, Metabolic Solutions Development Company, Mitsubishi Tanabe Pharma, Novartis, NGM Bio, NuSirt Biopharma, Oramed, Peptron, Pfizer, PhaseBio, Poxel, Sanwa Kagaku Kenkyusho, Sirona Biochem, Takeda, Theracos, Theratechnologies, Transition Therapeutics, VeroScience, vTv Therapeutics, XBiotech.